Recent genome-wide association studies have identified five loci (BIN1, CLU, CR1, EXOC3L2 and PICALM) as genetic determinants of Alzheimer's disease (AD). We attempted to confirm the association between these genes and the AD risk in three contrasting European populations (from Finland, Italy and Spain). Since CLU and CR1 had already been analyzed in these populations, we restricted our investigation to BIN1, EXO2CL3 and PICALM. In a total of 2,816 AD cases and 2,706 controls, we unambiguously replicated the association of rs744373 (for BIN1) and rs541458 (for PICALM) polymorphisms with the AD ). However, this signal did not appear to be independent of APOE.
Introduction
Although Alzheimer's disease (AD) is the most common cause of dementia in the elderly, its aetiology is still not fully understood. The characterization of causative factors is thus important for better defining the pathophysiological processes involved. In this context, the identification of genes involved in monogenic forms of AD has significantly contributed to our knowledge of the disease mechanisms (Bettens, 2010) . In contrast, the characterization of genetic factors involved in the common forms of AD (i.e. lacking classical Mendelian inheritance) has encountered significant difficulties; the apolipoprotein E (APOE) gene is the only globally valid genetic determinant of AD to have been unambiguously identified in 15 years of intensive research (Lambert, 2007) .
However, as with other multifactorial diseases, this systematic inability to detect new genetic determinants has prompted more comprehensive investigations using genome-wide association studies (GWASs). We and others performed three large GWASs in this field and reported that the CLU (clusterin), PICALM (phosphatidylinositol binding clathrin assembly protein), CR1 (complement component [3b/4b] receptor 1), BIN1 (bridging integrator 1) and EXOC3L2 (exocyst complex component 3-like 2) loci were associated with the AD risk (Harold, 2009; Lambert, 2009; Seshadri, 2010) .
To help to clarify the relevance of these genes as genetic determinants of AD, we analyzed their associations in contrasting European populations from Finland (n=1,123), Italy (n=2,811) and Spain (n=1,588). Since CLU and CR1 have been already studied in these populations (Lambert, 2009), we only tested single-nucleotide polymorphisms (SNPs) within PICALM, BIN1 and EXOC3L2.
Materials and Methods
All clinical diagnoses of probable AD were established according to the DSM-III-R and NINCDS-ADRDA criteria. Controls were defined as subjects not meeting the DMS-III-R dementia criteria and with intact cognitive functions (MMS>25). Written, informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian, or other proxy. The study protocols for all populations were reviewed and approved by the appropriate independent ethics committees in each country.
Information on age and gender in the cases and controls included in the study are shown in Table 1 . Samples with missing age or gender data were excluded, yielding a total of 2,816 AD cases and 2,706 controls.
Genotyping for the SNPs (rs744373 in BIN1, rs597668 in EXOC3L2 and rs541458 in PICALM) was performed with a Taqman system (Applied Biosystems). The primer and probe sequences are available on request. In order to avoid bias, cases and controls were randomly mixed when genotyping and the laboratory personnel were blinded to case/control status. The genotyping success rate was at least 95% and no departure from HardyWeinberg equilibrium was observed for the markers (Table 2) .
We undertook logistic regression analyses in each country (Finland, Italy and Spain) using an additive genetic model which took account of age, gender, disease status and (when necessary) centre. All analyses were performed with SAS software (release 9.1, SAS Institute, Cary, NC, USA). We then used inverse-variance weighting (also known as fixedeffects meta-analysis) with adjustments for age and gender for the overall effect assessment, using Review Manager software (release 5.0). Interactions between BIN1, EXOC3L2, PICALM and APOE ε4 polymorphisms were tested in logistic regression models adjusted for age, gender and (when necessary) centre. We again used inverse-variance weighting, with adjustments for age and gender for assessment of the overall interaction. Linkage disequilibrium was assessed using Haploview software.
Results
In each data set, we evaluated the association of AD with the rs744373, rs597668 and rs541458 SNPs within the BIN1, EXOC3L2 and PICALM loci, respectively. Even though the detected associations were not always statistically significant in all data sets, they were comparable in direction in the three different European populations. When the data sets were examined in a meta-analysis, we found strong evidence of associations for BIN1 (OR=1.26, p=2.9x10 ) and, to a lesser extent, EXOC3L2 (OR=1.19, p=2.0x10 -3 ) ( Table 3) .
We also searched for significant interactions between these three loci and APOE but failed to identify any in either the independent data sets or in the meta-analysis. We nevertheless reevaluated the association of the BIN1, PICALM and EXOC3L2 SNPs with the AD risk by adjusting for age, gender and the presence of at least one APOE ε4 allele. Whereas the BIN1 and PICALM associations were not modified (data not shown), we found no evidence of an association of EXOC3L2 with the AD risk after adjustment of the data sets taken individually (Finland, OR=0.91, p=4.2x10 ).
Discussion
Over recent months, our picture of the genetics of AD has changed greatly and suggests that most of the genuine genetic determinants of this disease will differ from those suspected before the advent of the GWASs (Laumet, 2010; Sleegers, 2010) . By looking at contrasting European populations of AD cases and controls in which the associations of CLU and CR1
with AD had already replicated (Lambert, 2009), we confirmed the association of PICALM and BIN1 with the AD risk. The ORs are comparable in direction and magnitude with those originally reported. The association of PICALM with the AD risk has been already replicated in several large data sets (Carrasquillo, 2010; Corneveaux, 2010; Jun, in press; Kamboh, in press; Seshadri, 2010 , p for heterogeneity=0.27).
To the best of our knowledge, our study is the first to have replicated the association of the BIN1 and EXOC3L2 loci with the AD risk. The meta-analysis of our data and those gathered =0.075 at most, in the Finland data set). This locus thus deserves more attention, in order to confirm or refute its association with the AD risk.
In conclusion, we unambiguously replicated the association of the PICALM and BIN1 loci (both of which code for proteins involved in endocytosis and clathrin-mediated synaptic vessel formation (Harel, 2008; Wigge, 1997) ) with the AD risk in contrasting European populations. In order to determine the exact implication of BIN1 and PICALM in AD, it is now essential to develop major, systematic, ambitious efforts in sequencing and genotyping (even for rare variants), together with replication in large, independent populations and functional analyses of intermediate phenotypes.
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